相似文献
1
Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).
Tetrahedron Lett. 2015 May 20;56(21):2832-2835. doi: 10.1016/j.tetlet.2015.04.061.
2
Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5971-4. doi: 10.1016/j.bmcl.2013.08.057. Epub 2013 Aug 21.
3
Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.
Bioorg Med Chem. 2016 Apr 1;24(7):1573-81. doi: 10.1016/j.bmc.2016.02.032. Epub 2016 Feb 26.
4
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.
Bioorg Med Chem Lett. 2014 Sep 1;24(17):4084-9. doi: 10.1016/j.bmcl.2014.07.063. Epub 2014 Jul 30.
5
Exploring the Activity Profile of TbrPDEB1 and hPDE4 Inhibitors Using Free Energy Perturbation.
ACS Med Chem Lett. 2022 May 23;13(6):904-910. doi: 10.1021/acsmedchemlett.1c00690. eCollection 2022 Jun 9.
6
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2).
Bioorg Med Chem. 2019 Sep 15;27(18):4013-4029. doi: 10.1016/j.bmc.2019.06.026. Epub 2019 Jul 5.
7
Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei.
Chem Biol Drug Des. 2015 May;85(5):549-64. doi: 10.1111/cbdd.12443. Epub 2014 Nov 18.
8
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors.
Bioorg Med Chem. 2019 Sep 15;27(18):3998-4012. doi: 10.1016/j.bmc.2019.06.027. Epub 2019 Jun 18.
9
Targeting a Subpocket in Trypanosoma brucei Phosphodiesterase B1 (TbrPDEB1) Enables the Structure-Based Discovery of Selective Inhibitors with Trypanocidal Activity.
J Med Chem. 2018 May 10;61(9):3870-3888. doi: 10.1021/acs.jmedchem.7b01670. Epub 2018 May 1.
10
Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure.
J Med Chem. 2013 Mar 14;56(5):2087-96. doi: 10.1021/jm3017877. Epub 2013 Mar 1.
引用本文的文献
1
Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice.
Nat Commun. 2024 Sep 27;15(1):8272. doi: 10.1038/s41467-024-52658-y.
2
Synthesis of new Spiropyrazole derivatives under microwaves irradiation and docking study for inhibition the microbes and COVID-19.
J Mol Struct. 2022 Dec 5;1269:133581. doi: 10.1016/j.molstruc.2022.133581. Epub 2022 Jun 25.
3
Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect.
Eur J Med Chem. 2020 Jan 15;186:111893. doi: 10.1016/j.ejmech.2019.111893. Epub 2019 Nov 16.
4
Synthesis of diN-Substituted Glycyl-Phenylalanine Derivatives by Using Ugi Four Component Reaction and Their Potential as Acetylcholinesterase Inhibitors.
Molecules. 2019 Jan 6;24(1):189. doi: 10.3390/molecules24010189.
5
The ever unfolding story of cAMP signaling in trypanosomatids: vive la difference!
Front Pharmacol. 2015 Sep 7;6:185. doi: 10.3389/fphar.2015.00185. eCollection 2015.
本文引用的文献
1
Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.
Bioorg Med Chem Lett. 2014 Sep 1;24(17):4084-9. doi: 10.1016/j.bmcl.2014.07.063. Epub 2014 Jul 30.
2
Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1).
Bioorg Med Chem Lett. 2013 Nov 1;23(21):5971-4. doi: 10.1016/j.bmcl.2013.08.057. Epub 2013 Aug 21.
3
A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis.
Pathog Glob Health. 2013 Jul;107(5):242-52. doi: 10.1179/2047773213Y.0000000105.
4
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
J Med Chem. 2012 Oct 25;55(20):8903-25. doi: 10.1021/jm3011838. Epub 2012 Oct 12.
5
Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.
J Med Chem. 2012 Oct 25;55(20):8745-56. doi: 10.1021/jm301059b. Epub 2012 Oct 8.
6
Pharmacological validation of Trypanosoma brucei phosphodiesterases as novel drug targets.
J Infect Dis. 2012 Jul 15;206(2):229-37. doi: 10.1093/infdis/jir857. Epub 2012 Jan 30.
7
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
J Med Chem. 2011 Dec 8;54(23):8188-94. doi: 10.1021/jm201148s. Epub 2011 Nov 8.
8
Target repurposing for neglected diseases.
Future Med Chem. 2011 Aug;3(10):1307-15. doi: 10.4155/fmc.11.92.
9
Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties.
J Med Chem. 2011 May 26;54(10):3669-73. doi: 10.1021/jm200144j. Epub 2011 Apr 21.
10
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Lancet. 2009 Jul 4;374(9683):56-64. doi: 10.1016/S0140-6736(09)61117-X. Epub 2009 Jun 24.
Zotero 插件